Literature DB >> 30196840

Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis.

Ilaria Rossetti1, Laura Zambusi2, Annamaria Finardi3, Antonella Bodini4, Luciano Provini5, Roberto Furlan6, Stefano Morara7.   

Abstract

Activation states of immune cells (among them, the so-called pro- or anti-inflammatory states) influence the pathogenesis of multiple sclerosis (MS). The neuropeptide calcitonin gene-related peptide (CGRP) can exert a pro- or anti-inflammatory role in a context-dependent manner. In mice CGRP was found to attenuate the development of experimental autoimmune encephalomyelitis (EAE, a common MS animal model). We analyzed CGRP effects on the expression of cytokines and markers of activation states, as well as its intracellular cascade, following intrathecal administration during EAE immunization. Real Time quantitative-PCR (RT-PCR) showed that IL-1beta and IL-6 (associated to a pro-inflammatory state in EAE), but also Ym1 (also known as Chil3), Arg1 and CD163 (associated to an anti-inflammatory state in EAE) were decreased in the encephalon (devoid of cerebellum). In the cerebellum itself, IL-1beta and Ym1 were decreased. TNF-alpha (associated to a pro-inflammatory state in EAE), but also IL-10 (associated to another type of anti-inflammatory state) and BDNF were unchanged in these two regions. No changes were detected in the spinal cord. Additional tendencies toward a change (as revealed by RT-PCR) were again decreases: IL-10 in the encephalon and Arg1 in the spinal cord. CGRP decreased percentage of Ym1+/CD68+ immunoreactive cells and cell density of infiltrates in the cervical spinal cord pia mater. Instead, Ym1 in the underlying parenchyma and at thoracic and lumbar levels, as well as Arg1, were unchanged. In cultured microglia the neuropeptide decreased Ym1, but not Arg1, immunoreactivity. Inducible NOS (iNOS) was unchanged in spinal cord microglia and astrocytes. The neuropeptide increased the activation of ERK1/2 in the astrocytes of the spinal cord and in culture, but did not influence the activation of ERK1/2 or p38 in the spinal cord microglia. Finally, in areas adjacent to infiltration sites CGRP-treated microglia showed a larger ramification radius. In conclusion, CGRP-induced EAE amelioration was associated to a concomitant, context-dependent decrease in the expression of markers belonging to both pro- or anti-inflammatory activation states of immune cells. It can be hypothesized that CGRP-induced EAE attenuation is obtained through a novel mechanism that promotes down-regulation of immune cell activation that facilitates the establishment of a beneficial environment in EAE provided possibly also by other factors.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory; CGRP; EAE; Homeostasis; Multiple sclerosis; Pro-inflammatory

Mesh:

Substances:

Year:  2018        PMID: 30196840     DOI: 10.1016/j.jneuroim.2018.07.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Cerebrospinal Fluid α-Calcitonin Gene-Related Peptide: A Comparison between Alzheimer's Disease and Multiple Sclerosis.

Authors:  Giulio Papiri; Arianna Vignini; Luigi Capriotti; Paola Verdenelli; Sonila Alia; Alice Di Paolo; Chiara Fiori; Sara Baldinelli; Mauro Silvestrini; Simona Luzzi
Journal:  Biomolecules       Date:  2022-01-24

2.  Conservation of mechanisms regulating emotional-like responses on spontaneous nicotine withdrawal in zebrafish and mammals.

Authors:  Luisa Ponzoni; Gloria Melzi; Laura Marabini; Andrea Martini; Giulia Petrillo; Muy-Teck Teh; Jose V Torres-Perez; Stefano Morara; Cecilia Gotti; Daniela Braida; Caroline H Brennan; Mariaelvina Sala
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-04-24       Impact factor: 5.067

3.  Lipocalin-2 may produce damaging effect after cerebral ischemia by inducing astrocytes classical activation.

Authors:  Nan Zhao; Xiaomeng Xu; Yongjun Jiang; Jie Gao; Fang Wang; Xiaohui Xu; Zhuoyu Wen; Yi Xie; Juanji Li; Rongrong Li; Qiushi Lv; Qian Liu; Qiliang Dai; Xinfeng Liu; Gelin Xu
Journal:  J Neuroinflammation       Date:  2019-08-19       Impact factor: 8.322

4.  Deletion of arginase 2 attenuates neuroinflammation in an experimental model of optic neuritis.

Authors:  Amritha A Candadai; Fang Liu; Abdelrahman Y Fouda; Moaddey Alfarhan; Chithra D Palani; Zhimin Xu; Ruth B Caldwell; S Priya Narayanan
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

Review 5.  Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.

Authors:  Mirella Russo; Matteo A De Rosa; Dario Calisi; Stefano Consoli; Giacomo Evangelista; Fedele Dono; Matteo Santilli; Alberto Granzotto; Marco Onofrj; Stefano L Sensi
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

6.  β-Funaltrexamine Displayed Anti-inflammatory and Neuroprotective Effects in Cells and Rat Model of Stroke.

Authors:  Chih-Cheng Wu; Cheng-Yi Chang; Kuei-Chung Shih; Chih-Jen Hung; Ya-Yu Wang; Shih-Yi Lin; Wen-Ying Chen; Yu-Hsiang Kuan; Su-Lan Liao; Wen-Yi Wang; Chun-Jung Chen
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

7.  Neuronal Conditional Knockout of Collapsin Response Mediator Protein 2 Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis.

Authors:  Aubin Moutal; Sergey Kalinin; Kathy Kowal; Natalia Marangoni; Jeffrey Dupree; Shao Xia Lin; Kinga Lis; Lucia Lisi; Kenneth Hensley; Rajesh Khanna; Douglas L Feinstein
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.